Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Journal of Clinical Medicine (2020) 9:9, 2903. https://doi.org/10.3390/jcm9092903
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2022
- Creator
-
Constantinescu, Catalin
Pasca, Sergiu
Zimta, Alina-Andreea
Tat, Tiberiu
Rus, Ioana
Teodorescu, Patric
Iluta, Sabina
Tanase, Alina
Colita, Anca
Sigurjonsson, Olafur
Einsele, Hermann
Tomuleasa, Ciprian
- DOI
-
10.3390/jcm9092903
- URN
-
urn:nbn:de:bvb:20-opus-213020
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:52 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Constantinescu, Catalin
- Pasca, Sergiu
- Zimta, Alina-Andreea
- Tat, Tiberiu
- Rus, Ioana
- Teodorescu, Patric
- Iluta, Sabina
- Tanase, Alina
- Colita, Anca
- Sigurjonsson, Olafur
- Einsele, Hermann
- Tomuleasa, Ciprian
- Universität Würzburg
Time of origin
- 2022
Other Objects (12)
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
![[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer](/assets/placeholder/searchResultMediaUnknown.png)
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Catalogue of approved English Books
Mutational processes of thoracic malignancies
FDA
FDA
FDA
FDA
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Catalogue of approved English Books
Mutational processes of thoracic malignancies
FDA
FDA
FDA
FDA
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Catalogue of approved English Books
Mutational processes of thoracic malignancies
FDA
FDA
FDA